Patents Assigned to Genentech
  • Nucleic acids encoding PRO943
    Patent number: 7101687
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • WISP polypeptides and nucleic acids encoding same
    Patent number: 7101850
    Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Arnold J. Levine, Diane Pennica
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Publication number: 20060194283
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: January 27, 2006
    Publication date: August 31, 2006
    Applicant: Genentech, Inc.
    Inventors: Kevin Baker, Maureen Beresini, Laura DeForge, Luc Desnoyers, Ellen Filvaroff, Wei-Qiang Gao, Mary Gerritsen, Audrey Goddard, Paul Godowski, Austin Gurney, Steven Sherwood, Victoria Smith, Timothy Stewart, Daniel Tumas, Colin Watanabe, William Wood, Zemin Zhang
  • Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
    Patent number: 7097840
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: August 29, 2006
    Assignees: Genentech, Inc., Immunogen, Inc.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • PRO 1384 nucleic acids
    Patent number: 7098003
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: August 29, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Extending time to disease progression or survival in cancer patients
    Publication number: 20060188509
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: February 21, 2006
    Publication date: August 24, 2006
    Applicant: Genentech, Inc.
    Inventors: Mika Derynck, Stephen Kelsey
  • Modulation of eNOS activity and therapeutic uses thereof
    Publication number: 20060188503
    Abstract: The present invention provides uses of VEGF or VEGF receptor agonists for the up-regulation of eNOS expression and activity. VEGF and VEGF receptor agonists are useful in the treatment of or prevention from hypertension, diabetes, angina, thrombosis, atherosclerosis, heart failure, and other conditions or disorders wherein nitric oxide is an important regulator.
    Type: Application
    Filed: February 2, 2006
    Publication date: August 24, 2006
    Applicant: Genentech, Inc.
    Inventors: Ben-Quan Shen, Thomas Zioncheck
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Patent number: 7094869
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: August 22, 2006
    Assignee: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7094567
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: August 22, 2006
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Giang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Jennie P. Mather, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
  • Novel composition and methods for the treatment of psoriasis
    Publication number: 20060182755
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis.
    Type: Application
    Filed: September 10, 2003
    Publication date: August 17, 2006
    Applicant: Genentech, Inc.
    Inventors: Sarah Bodary-Winter, Hilary Clark, Janet Jackman, Jill Schoenfeld, William Wood, Thomas Wu
  • Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
    Publication number: 20060182751
    Abstract: The invention relates to bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) compounds represented by Formula I: Ab-(L-D)p ??I where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked, through the wavy line, by a linker (L) to an antibody (Ab). The invention also relates to heterocyclic-substituted 1,8 bis-naphthalimide compounds having Formula XV The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC or Formula XV heterocyclic-substituted 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a Formula I ADC or Formula XV compound.
    Type: Application
    Filed: January 30, 2006
    Publication date: August 17, 2006
    Applicant: Genentech, Inc.
    Inventors: Lewis Gazzard, Edward Ha, David Jackson, Joann Um
  • Human growth hormone antagonists
    Publication number: 20060183784
    Abstract: A method is disclosed for treating disorders in which human growth hormone is implicated by administering to a mammal an effective amount of an antagonist according to the general formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein.
    Type: Application
    Filed: April 10, 2006
    Publication date: August 17, 2006
    Applicant: Genentech, Inc.
    Inventor: Andrea Cochran
  • Guanylate-binding protein
    Patent number: 7091178
    Abstract: A member of the guanylate-binding protein family, designated GBP-4, is provided. Also provided are isolated nucleic acid encoding GBP-4, vectors and host cells containing such nucleic acid molecule, and a method for producing the GBP-4 recombinantly.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: August 15, 2006
    Assignee: Genentech, Inc.
    Inventor: Diane Pennica
  • Vascular endothelial cell growth factor variants and uses thereof
    Patent number: 7090834
    Abstract: The present invention provides VEGF variants having one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: August 15, 2006
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, Abraham M. de Vos, Bing Li
  • Diagnosis and treatment of hepatic disorders
    Patent number: 7090845
    Abstract: The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration of an agent which prevents the interaction of MAdCAM with a MAdCAM binding partner or ligand. These compositions are useful in treating diseases or disorders involving ?4?7/MAdCAM blockade, as well as inhibiting a primary event in the inflammatory response such as blocking interactions between intercellular adhesion molecules and their ligands. Disorders treatable using the methods disclosed herein include infections, especially viral infections, iatrogenic disorders, cholestatic disorders, hereditary disorders, sarcoidosis, organ transplant, and the like. The diagnostic methods of the invention can be employed to detect the presence of a disorder or to monitor the course of therapy used to treat the disorder.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: August 15, 2006
    Assignee: Genentech, Inc.
    Inventors: Sherman Fong, Kenneth J. Hillan
  • Methods for Treating Autoimmune Disorders
    Publication number: 20060177436
    Abstract: The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune disorder is at least partially mediated by CD8+ T-cell proliferation.
    Type: Application
    Filed: December 16, 2005
    Publication date: August 10, 2006
    Applicant: GENENTECH, INC.
    Inventors: Nico Ghilardi, Frederic DeSauvage
  • Polypeptides that bind an anti-tissue factor antibody and uses thereof
    Publication number: 20060177446
    Abstract: The present invention relates to antibodies and polypeptides useful in blocking the binding of antibodies to anti-tissue factor, decreasing the activity of the anti-tissue factor antibodies and/or neutralizing the activity of an anti-tissue factor antibody. The present invention also relates to nucleic acids encoding the antibodies and polypeptides and compositions comprising the antibodies or polypeptides or nucleic acid molecules. The present invention provides methods of treating a hypercoagulable state or an inflammatory disease using the antibodies and polypeptides of this invention and other methods of using said antibodies and polypeptides.
    Type: Application
    Filed: November 29, 2005
    Publication date: August 10, 2006
    Applicant: GENENTECH, INC.
    Inventors: Charles Eigenbrot, Yu-Ju Meng, Daniel Kirchhofer, Leonard Presta
  • Inhibiting HER2 shedding with matrix metalloprotease antagonists
    Publication number: 20060177448
    Abstract: The present application describes using antagonists of matrix metalloproteases (MMPs), especially of MMP-15, for inhibiting HER2 shedding.
    Type: Application
    Filed: February 9, 2006
    Publication date: August 10, 2006
    Applicant: Genentech, Inc.
    Inventors: Kendall Carey, Ralph Schwall, Mark Sliwkowski, Gail Schwall
  • PR1550 polypeptides and nucleic acids encoding the same
    Publication number: 20060177897
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: July 27, 2005
    Publication date: August 10, 2006
    Applicant: Genentech, Inc.
    Inventors: Audrey Goddard, Paul Godowski, J. Grimaldi, Austin Gurney, Colin Watanabe, William Wood
  • PRO1306 nucleic acids
    Patent number: 7087404
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: August 8, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Dan L. Eaton, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood